PDF(Pubmed)
Abstract：
UNASSIGNED: We conducted a comprehensive systematic review to examine the efficacy of intensive blood pressure lowering on the risk of left ventricular hypertrophy (LVH).
UNASSIGNED: We searched PubMed, Scopus, Web of Science, Cochrane Central, and EMBASE for all relevant randomized controlled trials. The primary outcome was the incidence of left ventricular hypertrophy. We used the risk ratio (RR) and hazard ratio (HR) with a 95% confidence interval as our effect sizes.
UNASSIGNED: Four studies, comprising 20,747 patients, were included. Intensive blood pressure lowering was linked with a diminished LVH incidence (RR: 0.66, 95% CI [0.56-0.77]). We also found that intensive blood pressure lowering increased the risk of LVH regression in patients with baseline LVH (RR: 1.21, 95% CI [1.11-1.32]). Finally, intensive blood pressure lowering was linked with a reduced risk of cardiovascular disease (HR: 0.71, 95% CI [0.60-0.85]). No significant heterogeneity was seen in either outcome.
UNASSIGNED: Our study suggests that intensive blood pressure lowering effectively reduces the risk of LVH and cardiovascular disease. An interactive version of our analysis can be accessed here: https://databoard.shinyapps.io/lvh_hypertophy/.
UNASSIGNED: We searched PubMed, Scopus, Web of Science, Cochrane Central, and EMBASE for all relevant randomized controlled trials. The primary outcome was the incidence of left ventricular hypertrophy. We used the risk ratio (RR) and hazard ratio (HR) with a 95% confidence interval as our effect sizes.
UNASSIGNED: Four studies, comprising 20,747 patients, were included. Intensive blood pressure lowering was linked with a diminished LVH incidence (RR: 0.66, 95% CI [0.56-0.77]). We also found that intensive blood pressure lowering increased the risk of LVH regression in patients with baseline LVH (RR: 1.21, 95% CI [1.11-1.32]). Finally, intensive blood pressure lowering was linked with a reduced risk of cardiovascular disease (HR: 0.71, 95% CI [0.60-0.85]). No significant heterogeneity was seen in either outcome.
UNASSIGNED: Our study suggests that intensive blood pressure lowering effectively reduces the risk of LVH and cardiovascular disease. An interactive version of our analysis can be accessed here: https://databoard.shinyapps.io/lvh_hypertophy/.
摘要：
■我们进行了全面的系统评价，以检查强化降压对左心室肥厚（LVH）风险的功效。
■我们搜索了PubMed，Scopus,WebofScience,CochraneCentral,和EMBASE用于所有相关的随机对照试验。主要结果是左心室肥厚的发生率。我们使用95%置信区间的风险比(RR)和风险比(HR)作为我们的效应大小。
■四项研究，包括20747名患者,包括在内。强化血压降低与LVH发生率降低相关(RR:0.66,95%CI[0.56-0.77])。我们还发现，强化降压增加了基线LVH患者LVH消退的风险（RR：1.21，95%CI[1.11-1.32]）。最后,强化降压与心血管疾病风险降低相关(HR:0.71,95%CI[0.60-0.85]).两种结果均未见显著异质性。
■我们的研究表明，强化降压可有效降低LVH和心血管疾病的风险。我们的分析的交互式版本可以在这里访问：https://databoard。shinyapps.io/lvh_hypertophy/.
■我们搜索了PubMed，Scopus,WebofScience,CochraneCentral,和EMBASE用于所有相关的随机对照试验。主要结果是左心室肥厚的发生率。我们使用95%置信区间的风险比(RR)和风险比(HR)作为我们的效应大小。
■四项研究，包括20747名患者,包括在内。强化血压降低与LVH发生率降低相关(RR:0.66,95%CI[0.56-0.77])。我们还发现，强化降压增加了基线LVH患者LVH消退的风险（RR：1.21，95%CI[1.11-1.32]）。最后,强化降压与心血管疾病风险降低相关(HR:0.71,95%CI[0.60-0.85]).两种结果均未见显著异质性。
■我们的研究表明，强化降压可有效降低LVH和心血管疾病的风险。我们的分析的交互式版本可以在这里访问：https://databoard。shinyapps.io/lvh_hypertophy/.
